Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 24;11(5):e0156113.
doi: 10.1371/journal.pone.0156113. eCollection 2016.

Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology

Umberto Vespasiani-Gentilucci  1 , Paolo Gallo  1 , Fiorella Piemonte  2 , Elisabetta Riva  3 , Aldostefano Porcari  1 , Ferruccio Vorini  1 , Giulia Tozzi  2 , Livia Piccioni  3 , Giovanni Galati  1 , Antonio De Vincentis  1 , Simone Carotti  4 , Sergio Morini  4 , Jessica D'Amico  2 , Silvia Angeletti  5 , Claudio Pedone  6 , Antonio Picardi  1
Affiliations

Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology

Umberto Vespasiani-Gentilucci et al. PLoS One. .

Abstract

Liver cirrhosis is characterized by a severe acquired reduction of LAL-activity, the precise causes and consequences of which need to be further addressed. DBS-determined lysosomal enzyme activities seem to be affected by white blood cell and platelet counts, and the specificity of these tests can be reduced when applied to determined populations, such as cirrhotics.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
DBS-determined LAL activity in cryptogenic cirrhotics, cirrhotics of known etiology and healthy subjects (Panel A). Percentages of cirrhotic patients and healthy subjects with normal (≥0.8 nmol/spot/h), mildly reduced (range 0.4–0.8 nmol/spot/h), or severely reduced LAL activity (<0.4 nmol/spot/h) (Panel B).
See this image and copyright information in PMC

References

    1. Reiner Ž, Guardamagna O, Nair D, Soran H, Hovingh K, Bertolini S, et al. J. Lysosomal acid lipase deficiency—an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014;235:21–30. 10.1016/j.atherosclerosis.2014.04.003 - DOI - PubMed
    1. Muntoni S, Wiebusch H, Jansen-Rust M, Rust S, Seedorf U, Schulte H, et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 2007;27:1866–8. - PubMed
    1. Lohse P, Maas S, Lohse P, Elleder M, Kirk JM, Besley GT, et al. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res 2000;41:23–31. - PubMed
    1. Hoffman EP, Barr ML, Giovanni MA, Murray MF. Lysosomal Acid Lipase Deficiency In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, eds. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993–2016.
    1. Bernstein DL, Hülkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol 2013;58:1230–43. 10.1016/j.jhep.2013.02.014 - DOI - PubMed

Supplementary concepts